SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/21 Teladoc Health, Inc. 10-K 12/31/20 126:15M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.19M 2: EX-4.11 Instrument Defining the Rights of Security Holders HTML 43K 4: EX-10.14 Material Contract HTML 55K 5: EX-10.15 Material Contract HTML 58K 6: EX-10.16 Material Contract HTML 55K 7: EX-10.18 Material Contract HTML 46K 3: EX-10.2 Material Contract HTML 130K 8: EX-21.1 Subsidiaries List HTML 39K 9: EX-23.1 Consent of Expert or Counsel HTML 35K 10: EX-31.1 Certification -- §302 - SOA'02 HTML 39K 11: EX-31.2 Certification -- §302 - SOA'02 HTML 39K 12: EX-32.1 Certification -- §906 - SOA'02 HTML 35K 13: EX-32.2 Certification -- §906 - SOA'02 HTML 35K 20: R1 Document and Entity Information HTML 96K 21: R2 Consolidated Balance Sheets HTML 123K 22: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K 23: R4 Consolidated Statements of Operations HTML 93K 24: R5 Consolidated Statements of Comprehensive Loss HTML 55K 25: R6 Consolidated Statements of Stockholders' Equity HTML 131K 26: R7 Consolidated Statements of Cash Flows HTML 159K 27: R8 Organization and Description of Business HTML 39K 28: R9 Summary of Significant Accounting Policies HTML 117K 29: R10 Revenue, Deferred Revenue, Deferred Costs and HTML 118K Other 30: R11 Fair Value Measurements HTML 84K 31: R12 Business Acquisitions HTML 103K 32: R13 Inventories HTML 43K 33: R14 Property and Equipment, Net HTML 57K 34: R15 Intangible Assets, Net HTML 123K 35: R16 Goodwill HTML 49K 36: R17 Accrued Expenses and Other Current Liabilities HTML 63K 37: R18 Revolving Credit Facility HTML 34K 38: R19 Convertible Senior Notes HTML 185K 39: R20 Advances from Financing Companies HTML 45K 40: R21 Leases and Contractual Obligations HTML 69K 41: R22 Common Stock and Stockholders' Equity HTML 180K 42: R23 Income Taxes HTML 186K 43: R24 Sale of Assets HTML 34K 44: R25 Net Loss per Share HTML 53K 45: R26 401(k) Plan HTML 36K 46: R27 Legal Matters HTML 41K 47: R28 Subsequent Event HTML 35K 48: R29 Schedule II - Valuation and Qualifying Accounts HTML 94K 49: R30 Summary of Significant Accounting Policies HTML 188K (Policies) 50: R31 Summary of Significant Accounting Policies HTML 38K (Tables) 51: R32 Revenue, Deferred Revenue, Deferred Costs and HTML 112K Other (Tables) 52: R33 Fair Value Measurements (Tables) HTML 82K 53: R34 Business Acquisitions (Tables) HTML 98K 54: R35 Inventories (Tables) HTML 44K 55: R36 Property and Equipment, Net (Tables) HTML 56K 56: R37 Intangible Assets, Net (Tables) HTML 125K 57: R38 Goodwill (Tables) HTML 49K 58: R39 Accrued Expenses and Other Current Liabilities HTML 63K (Tables) 59: R40 Convertible Senior Notes (Tables) HTML 152K 60: R41 Advances from Financing Companies (Tables) HTML 43K 61: R42 Leases and Contractual Obligations (Tables) HTML 68K 62: R43 Common Stock and Stockholders' Equity (Tables) HTML 165K 63: R44 Income Taxes (Tables) HTML 183K 64: R45 Net Loss per Share (Tables) HTML 51K 65: R46 Summary of Significant Accounting Policies - VIE HTML 69K (Details) 66: R47 Summary of Significant Accounting Policies - HTML 46K Segment Information (Details) 67: R48 Summary of Significant Accounting Policies - Cash HTML 37K and Cash Equivalents and Short-Term Investments (Details) 68: R49 Summary of Significant Accounting Policies - PPE HTML 42K (Details) 69: R50 Summary of Significant Accounting Policies - HTML 43K Operating Leases (Details) 70: R51 Summary of Significant Accounting Policies - HTML 65K Intangibles (Details) 71: R52 Summary of Significant Accounting Policies - HTML 44K Stock-Based Compensation (Details) 72: R53 Summary of Significant Accounting Policies - HTML 34K Foreign Currency (Details) 73: R54 Summary of Significant Accounting Policies - HTML 34K Advertising and Marketing Expenses (Details) 74: R55 Summary of Significant Accounting Policies - HTML 42K Concentrations (Details) 75: R56 Revenue, Deferred Revenue, Deferred Costs and HTML 39K Other - Other Disclosures (Details) 76: R57 Revenue, Deferred Revenue, Deferred Costs and HTML 65K Other - Disaggregation and Other (Details) 77: R58 Revenue, Deferred Revenue, Deferred Costs and HTML 41K Other - Revenue Remaining Performance Obligation (Details) 78: R59 Revenue, Deferred Revenue, Deferred Costs and HTML 43K Other - Deferred Cost and Other (Details) 79: R60 Fair Value Measurements - Recurring (Details) HTML 62K 80: R61 Fair Value Measurements - Level 3 (Details) HTML 46K 81: R62 Business Acquisitions - Transactions (Details) HTML 64K 82: R63 Business Acquisitions - Assets Acquired, HTML 111K Liabilities Assumed, Pro forma (Details) 83: R64 Inventories (Details) HTML 42K 84: R65 Property and Equipment, Net (Details) HTML 50K 85: R66 Intangible Assets, Net - Summary (Details) HTML 87K 86: R67 Intangible Assets, Net - Amortization (Details) HTML 46K 87: R68 Goodwill (Details) HTML 39K 88: R69 Accrued Expenses and Other Current Liabilities HTML 63K (Details) 89: R70 Revolving Credit Facility (Details) HTML 46K 90: R71 Convertible Senior Notes - Due 2027 - Terms HTML 74K (Details) 91: R72 Convertible Senior Notes - Due 2027 - Summary HTML 58K (Details) 92: R73 Convertible Senior Notes - Livongo Notes Due 2025 HTML 68K - Terms (Details) 93: R74 Convertible Senior Notes - Livongo Notes Due 2025 HTML 58K - Summary (Details) 94: R75 Convertible Senior Notes - Due 2025 - Terms HTML 74K (Details) 95: R76 Convertible Senior Notes - Due 2025 - Summary HTML 59K (Details) 96: R77 Convertible Senior Notes - Due 2022 - Terms HTML 73K (Details) 97: R78 Convertible Senior Notes - Due 2022 - Summary HTML 59K (Details) 98: R79 Convertible Senior Notes - Due 2022 - Other HTML 47K (Details) 99: R80 Convertible Senior Notes - Extinguishment HTML 37K (Details) 100: R81 Advances from Financing Companies (Details) HTML 42K 101: R82 Leases and Contractual Obligations - Other HTML 54K (Details) 102: R83 Leases and Contractual Obligations - Lease Cost HTML 41K (Details) 103: R84 Leases and Contractual Obligations - Supplemental HTML 41K Information (Details) 104: R85 Leases and Contractual Obligations - Future HTML 49K Minimum Lease Payments (Details) 105: R86 Common Stock and Stockholders' Equity - HTML 46K Capitalization (Details) 106: R87 Common Stock and Stockholders' Equity (Deficit) - HTML 35K Warrants (Details) 107: R88 Common Stock and Stockholders' Equity - Stock Plan HTML 114K and Stock Options (Details) 108: R89 Common Stock and Stockholders' Equity - Fair Value HTML 64K Assumptions (Details) 109: R90 Common Stock and Stockholders' Equity - Restricted HTML 91K Stock Units (Details) 110: R91 Common Stock and Stockholders' Equity - HTML 84K Performance Stock Units (Details) 111: R92 Common Stock and Stockholders' Equity - Employee HTML 54K Stock Purchase Plan (Details) 112: R93 Common Stock and Stockholders' Equity - HTML 47K Compensation Costs (Details) 113: R94 Income Taxes - Components (Details) HTML 71K 114: R95 Income Taxes - Statutory Income Tax Rate HTML 57K Reconciliation (Details) 115: R96 Income Taxes - Deferred Tax Assets, Liabilities HTML 85K and Valuation Allowance (Details) 116: R97 Income Taxes - Carryforwards (Details) HTML 50K 117: R98 Income Taxes - Unrecognized Tax Benefits (Details) HTML 46K 118: R99 Sale of Assets (Details) HTML 36K 119: R100 Net Loss per Share (Details) HTML 59K 120: R101 401(k) Plan (Details) HTML 42K 121: R102 Subsequent Events (Details) HTML 36K 122: R103 Schedule II - Valuation and Qualifying Accounts HTML 47K (Details) 124: XML IDEA XML File -- Filing Summary XML 226K 19: XML XBRL Instance -- tdoc-20201231x10k_htm XML 3.53M 123: EXCEL IDEA Workbook of Financial Reports XLSX 155K 15: EX-101.CAL XBRL Calculations -- tdoc-20201231_cal XML 269K 16: EX-101.DEF XBRL Definitions -- tdoc-20201231_def XML 985K 17: EX-101.LAB XBRL Labels -- tdoc-20201231_lab XML 1.96M 18: EX-101.PRE XBRL Presentations -- tdoc-20201231_pre XML 1.58M 14: EX-101.SCH XBRL Schema -- tdoc-20201231 XSD 267K 125: JSON XBRL Instance as JSON Data -- MetaLinks 522± 809K 126: ZIP XBRL Zipped Folder -- 0001558370-21-002118-xbrl Zip 546K
Exhibit 31.1
Certification
I, Jason Gorevic, certify that:
1. | I have reviewed this Annual Report on Form 10-K of Teladoc Health, Inc. (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 1, 2021 |
| |
| | |
| | |
/s/ JASON GOREVIC | | |
| | |
Chief Executive Officer | | |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/1/21 | 4, S-8 | ||
For Period end: | 12/31/20 | 5 | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/24 Teladoc Health, Inc. 10-K 12/31/23 120:12M 3/01/23 Teladoc Health, Inc. 10-K 12/31/22 121:15M Toppan Merrill Bridge/FA 2/28/22 Teladoc Health, Inc. 10-K 12/31/21 111:14M Toppan Merrill Bridge/FA 3/01/21 Teladoc Health, Inc. S-8 3/01/21 3:102K Toppan Merrill/FA |